Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bristol-Myers posts...

    Bristol-Myers posts strong second quarter as Eliquis, Orencia sales propel

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-28T09:17:44+05:30  |  Updated On 16 Aug 2021 7:44 AM GMT

    Sales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both exceeding Wall Street expectations.


    NEW YORK: Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp (CELG.O) for $74 billion, posted a better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.


    Shares of the New York-based drugmaker were up 4.8% at $45.30 in afternoon trading.


    The earnings follow mixed results released on Wednesday from a closely watched lung cancer trial of its blockbuster immunotherapy Opdivo in combination with either chemotherapy or its other immuno-oncology drug, Yervoy.


    "While some of the drug data were disappointing, there was enough positivity for the combination of Opdivo and Yervoy that would suggest there is potential for that to gain share for a longer period of time," said Jeremy Bryan, portfolio manager at Gradient Investments.


    Sales of Eliquis, which Bristol-Myers shares with Pfizer Inc (PFE.N), rose 24% to $2.04 billion, while Orencia sales rose 9% to $778 million, both exceeding Wall Street expectations.


    Opdivo sales rose 12% to $1.82 billion.


    Despite the solid growth for Opdivo, there has been widespread investor concern over the dominance of rival drug Keytruda from Merck & Co (MRK.N) in the lucrative lung cancer market. Keytruda has surpassed Opdivo in sales in recent quarters and the company said it expects additional pressure on Opdivo sales next year.


    The latest lung cancer data is unlikely to allay those concerns.


    Opdivo combined with chemotherapy failed to extend overall survival more than chemotherapy alone as an initial treatment for advanced non-squamous non-small cell lung cancer (NSCLC). Keytruda plus chemotherapy has demonstrated a survival benefit in clinical trials.


    Opdivo did extend overall survival when used with Yervoy in certain NSCLC patients.

    https://pubads.g.doubleclick.net/gampad/ads?iu=/21687779244/clinicalkey_video_ad&description_url=[placeholder]&tfcd=0&npa=0&sz=640x480&gdfp_req=1&output=vast&unviewed_position_start=1&env=vp&impl=s&correlator=

    Some analysts and investors have suggested that one reason Bristol launched its bid for Celgene was over concerns about Opdivo losing ground to Keytruda.


    Bristol said it still expects the Celgene deal to close in late 2019 or early 2020.


    Excluding one-time items, the drugmaker said it earned $1.18 a share for the quarter, beating analysts' expectations by 11 cents, according to IBES data from Refinitiv.


    Bristol-Myers increased its full-year profit forecast by 10 cents and now expects to earn $4.20 to $4.30 a share.


    Revenue in the quarter was $6.27 billion, topping Wall Street expectations of $6.11 billion.


    The company reported a net profit of $1.43 billion, or 87 cents a share, compared with $373 million, or 23 cents a share, a year earlier.





    Reporting by Michael Erman, Additional reporting by Manas Mishra in Bengaluru; Editing by Cynthia Osterman, Susan Thomas, and Bill Berkrot


    Read Also: Bristol-Myers to sell blockbuster Otezla for its $74 billion merger with Celgene




    arthritis treatment Biotechnology company blood thinner Bristol-Myers cancer Celgene chemotherapy Eliquis immunotherapy Jeremy Bryan Keytruda Merck Michael Erman NSCLC oncology drug Opdivo ORENCIA Pfizer pharma pharma company pharma news revenue Yervoy 
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X